PALISADE BIO, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $250,000 | $0 | — |
| Research and development | $10.2M | $16.0M | $6.9M | $6.5M | $2.4M |
| Operating expenses | $18.1M | $14.9M | $13.3M | $15.7M | $41.9M |
| Operating income | -$18.1M | -$14.9M | -$13.1M | -$15.7M | -$41.9M |
| Interest expense | $10,000 | $12,000 | $15,000 | $13,000 | $2.4M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$16.8M | -$14.4M | -$12.3M | -$14.3M | -$26.6M |
| Balance Sheet | |||||
| Cash and equivalents | $133.4M | $9.8M | $12.4M | $12.4M | $10.5M |
| Current assets | $134.2M | $10.5M | $13.3M | $14.7M | $11.5M |
| Total assets | $134.3M | $10.9M | $14.1M | $15.8M | $12.5M |
| Current liabilities | $4.6M | $3.2M | $2.6M | $3.0M | $2.5M |
| Total liabilities | $5.0M | $3.4M | $2.7M | $3.3M | $5.1M |
| Total debt | — | — | — | — | $87,000 |
| Stockholders' equity | $129.4M | $7.5M | $11.3M | $12.5M | $7.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$10.8M | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
| Depreciation and amortization | $3,000 | $3,000 | $4,000 | $3,000 | $2,000 |
| Stock-based compensation | $4.0M | $652,000 | $624,000 | $1.0M | $1.9M |
| Capital expenditure | — | $0 | $4,000 | $10,000 | $0 |
| Free cash flow | — | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
Shares outstanding 173.6M · Free float 84.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.